KPV

Anti-inflammatory tripeptide · Also known as Lys-Pro-Val, alpha-MSH C-terminal tripeptide

What is kpv?

A naturally occurring tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It carries most of the anti-inflammatory activity of the parent hormone in a much smaller molecule.

KPV was identified through research into why alpha-MSH has such potent anti-inflammatory effects. Scientists found that just three amino acids (lysine-proline-valine) at the tail end of the hormone were responsible for much of its immune-modulating activity. It has been studied primarily in animal models of inflammatory bowel disease.

Key takeaway: KPV shows strong anti-inflammatory potential in preclinical IBD models, but human clinical trial data is still very limited.

Benefits & evidence

Gut inflammation reduction Moderate confidence
Intestinal barrier support Preliminary confidence
Skin inflammation relief Preliminary confidence
Immune modulation Preliminary confidence

How it works

KPV enters intestinal epithelial cells through the PepT1 transporter, a peptide transporter expressed on the surface of gut lining cells. Once inside, it inhibits the NF-kB signaling pathway, a master regulator of inflammation. By blocking NF-kB activation, KPV reduces production of pro-inflammatory cytokines like TNF-alpha and IL-1beta, dampening the inflammatory cascade at its source.

Unlike the full alpha-MSH hormone, KPV does not appear to work through melanocortin receptors. Its anti-inflammatory action is independent of the classical melanocortin pathway, which means it avoids the pigmentation side effects associated with other alpha-MSH-derived peptides like melanotan-II. KPV also appears to directly antagonize IL-1 activity, adding a second layer of anti-inflammatory action.

Dosing information

Typical dosing protocol
Starting dose

200-500 mcg/day

Weeks 1-4
Maintenance dose

500 mcg/day

4-12 week cycles

No human clinical trials have established optimal dosing for KPV itself. A related derivative (K(D)PT) was studied in a phase 2 trial for ulcerative colitis at oral doses of 20-100 mg twice daily for 8 weeks. Typical protocols use oral capsules or subcutaneous injection. Consult a healthcare provider.

Side effects

Most side effects tend to improve as your body adjusts.

Mild GI discomfort Common
Injection site irritation Common
Transient bloating Uncommon
Histamine sensitivity in susceptible individuals Uncommon

Research (10 studies)